We supply a diversified portfolio of branded prescription, OTC, consumer and
infant nutritional products into Australia and New Zealand. We are one of the
largest manufacturers in Australia and our manufacturing site in Melbourne
produces certain tablets, liquids and semi-solids.
Contribution to Group revenue
Revenue contribution - by therapeutic category
- The Australian pharmaceutical sector was valued at AUD18,3 billion as at 30 June 2017 with volume growth of 8,2%.
- Aspen is currently ranked 3rd by volume and 10th by value in the Australian pharmaceutical sector for the year ended 30 June 2017.
- Almost one in six scripts written in Australia is for a product distributed by Aspen.
Source: June 2017 IMS
Number of products launched:
IMS value of pipeline as at 30 June 2017 anticipated to be launched in:
0 – 2 years
3 – 5 years
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
Number of permanent employees:
|Revenue – R’billion||2017||2016 (CER)*||% change|
|High Potency & Cytotoxics||0,5||0,5||2|
|Other Commercial Pharmaceutical Brands||3,7||4,0||(9)|
* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.